KalVista Pharmaceuticals (NASDAQ:KALV) Given New $42.00 Price Target at Stifel Nicolaus

KalVista Pharmaceuticals (NASDAQ:KALV) had its target price lifted by Stifel Nicolaus from $39.00 to $42.00 in a report released on Thursday morning,Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.

Several other research analysts also recently issued reports on KALV. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. HC Wainwright raised their price objective on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Needham & Company LLC boosted their target price on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Citizens Jmp reduced their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Thursday. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.

KalVista Pharmaceuticals Price Performance

Shares of KALV stock opened at $18.95 on Thursday. KalVista Pharmaceuticals has a 52 week low of $9.23 and a 52 week high of $19.27. The stock has a market capitalization of $957.92 million, a PE ratio of -4.80 and a beta of -0.35. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The stock’s fifty day moving average is $15.95 and its 200-day moving average is $14.44.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, CFO Brian Piekos sold 1,767 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $27,512.19. Following the transaction, the chief financial officer directly owned 13,762 shares in the company, valued at $214,274.34. This trade represents a 11.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Nicole Sweeny sold 3,975 shares of KalVista Pharmaceuticals stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $61,890.75. Following the sale, the insider directly owned 47,003 shares of the company’s stock, valued at approximately $731,836.71. This trade represents a 7.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 33,378 shares of company stock worth $522,290 over the last quarter. 4.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in KALV. Vanguard Group Inc. grew its position in shares of KalVista Pharmaceuticals by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock worth $30,464,000 after buying an additional 88,720 shares during the period. Tudor Investment Corp ET AL acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at approximately $24,360,000. State Street Corp boosted its stake in KalVista Pharmaceuticals by 21.3% during the 4th quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock worth $30,874,000 after acquiring an additional 336,195 shares during the last quarter. Vestal Point Capital LP boosted its stake in KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock worth $30,524,000 after acquiring an additional 1,140,000 shares during the last quarter. Finally, Parkman Healthcare Partners LLC grew its holdings in KalVista Pharmaceuticals by 155.5% during the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after purchasing an additional 1,055,940 shares during the period.

Key KalVista Pharmaceuticals News

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Company reported $49.1M in EKTERLY revenue during an eight‑month transition period and highlighted a strong launch that supports topline growth expectations. KalVista posts $49.1 million in EKTERLY revenue
• Positive Sentiment: Corporate update and eight‑month FY2025 results emphasized commercial progress and operational updates that underpin near‑term revenue visibility. KalVista Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and kept a “buy” rating — implying ~122% upside from the current price — reflecting bullish analyst views on commercial execution and upside potential. Stifel raises KALV price target
• Positive Sentiment: Needham & Company increased its target from $35 to $36 and maintained a “buy” rating, signaling continued analyst confidence in EKTERLY’s market opportunity. Needham raises KALV price target
• Neutral Sentiment: Q1/8‑month earnings call transcripts (and related highlights) are available; these provide detail on revenue cadence, channel dynamics, and management commentary that investors should review for execution risk and guidance clarity. Q1 2025 earnings call transcript 8 Months 2025 earnings call transcript
• Negative Sentiment: Citizens Jmp trimmed its price target from $29 to $28 and moved to “market outperform” — a mild downgrade in target that could temper enthusiasm despite still-significant upside (~48%). Citizens Jmp lowers KALV price target

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.